Jobs / United States / Novartis Pharmaceuticals Corporation
Director, US BD&L and Commercial Mergers & Integrations
Novartis Pharmaceuticals Corporation · 🇺🇸 East Hanover
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Novartis Pharmaceuticals Corporation paid sponsored hires in similar roles7 certified filings for “Director, Resource Optimization Commercial” (Medical and Health Services Managers) in NJ: $183k–$223k, median $223k. Most were filed at wage level IV (67%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. The pay stated here ($176,400.00) is below what this employer usually pays sponsored hires for this role. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Novartis Pharmaceuticals Corporation
The US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Novartis Pharmaceuticals Corporation →
About the role
Job Description Summary The Director, US BD&L will work under the leadership of the ED US BD&L and Commercial Mergers & Integrations to partner with the an extended team of US cross functional experts providing strategic support across therapeutic areas, with a preference for candidates who bring relevant expertise through scientific, clinical, pipeline, commercial, or BD&L experience. This individual will help ensure strong US perspective and alignment across asset assessments, opportunity prioritization, and cross-functional input, while supporting effective partnership with the global team in Strategy and growth (BD&L) as well as the M&A group. The Director, US BD&L will offer strategic support in an agile way, depending on the priorities. This leader is expected to demonstrate accountability and responsibility for broader enterprise leadership in her/his decisions and engagement across the US Pharma organization and the Global Pharma Organization. This leader has a passion for transformational enterprise leadership, decisive strategy in service of delivering higher impact for patients, customers, healthcare systems with higher quality, speed and agility. Job Description Key Responsibilities: • Coordinate clear and timely US input across TA pipeline leads and relevant line functions to support high-quality BD&L assessments and recommendations. • In close collaboration with the data and insights team, integration of insights and recommendation for all sources of external data, including analysts’ reports, enterprise level competitive intelligence • Serve as an effective bridge between US stakeholders, Strategy & Growth, TASH, and Global teams to ensure aligned, actionable, and well-integrated US perspectives. • Lead cross-TA coverage, with a preferred core focus and deeper expertise in Cardiovascular/Cardiology and related pipeline areas, while remaining flexible and able to integrate knowledge across other therapeutic areas, including Neuroscience, Oncology, and Im-munology, as US BD&L priorities, bandwidth, and business needs evolve. • Support merger, acquisition, and integration preparedness by contributing to coordinated US BD&L input, while demonstrating the agility, operational discipline, and people-management skills needed to pivot and support integration work during an acquisition or other priority enterprise initiatives. Essential Requirements : Ideal Background /Experience: • Bachelor’s Degree required; MBA, scientific, clinical, or health policy degree preferred. • 8+ years of relevant pharmaceutical industry experience, such as commercial strategy, BD&L, pipeline strategy, insights and analytics, modeling, finance, access, or related functions. • Strong understanding of the commercialization process, pipeline assessment, coverage and reimbursement considerations, and cross-functional decision-making. Desirable Requirements: • Cardiovascular/Cardiology expertise preferred, ideally through scientific, clinical, pipeline, commercial, or BD&L experience. The salary for this position is expected to range between $176,400.00 and $327,600.00 per year. The final salary offered is determined based on factors like, but not limited to, relevant skills and experience, and upon joining Novartis will be reviewed periodically. Novartis may change the published salary range based on company and market factors. Your compensation will include a performance-based cash incentive and, depending on the level of the role, eligibility to be considered for annual equity awards. US-based eligible employees will receive a comprehensive benefits package that includes health, life and disability benefits, a 401(k) with company contribution and match, and a variety of other benefits. In addition, employees are eligible for a ge